ReviewThe European respiratory journal2009
High-throughput molecular analysis in lung cancer: insights into biology and potential clinical applications.
Review in The European respiratory journal, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 54 citations in OpenAlex.
- DNMT1 is associated with QDPR downregulation and chemotherapy response in lung adenocarcinoma.Medical oncology (Northwood, London, England) · 2026Article
- Single-cell N4-acetylcytidine regulatory landscape identifies ARIH1 as a ferroptosis-suppressive oncogenic driver in lung adenocarcinoma.Respiratory research · 2026Article
- Metabolic reprogramming and therapeutic targeting in non-small cell lung cancer: emerging insights beyond the Warburg effect.Frontiers in oncology · 2025Review
- Unravelling the Triad of Lung Cancer, Drug Resistance, and Metabolic Pathways.Diseases (Basel, Switzerland) · 2024Review
- miR-92a-3p regulates cisplatin-induced cancer cell death.Cell death & disease · 2023Article
- ARNTL2 upregulation of ACOT7 promotes NSCLC cell proliferation through inhibition of apoptosis and ferroptosis.BMC molecular and cell biology · 2023Article
- An immune-related nomogram model that predicts the overall survival of patients with lung adenocarcinoma.BMC pulmonary medicine · 2022Article
- Article
- The Downregulation ofJournal of personalized medicine · 2021Article
- Transcriptomic signals in blood prior to lung cancer focusing on time to diagnosis and metastasis.Scientific reports · 2021Article
- A Novel Six-Gene Signature for Prognosis Prediction in Ovarian Cancer.Frontiers in genetics · 2020Article
- Extracellular matrix gene expression profiling using microfluidics for colorectal carcinoma stratification.Biomicrofluidics · 2016Article
- Systems biology approaches to develop innovative strategies for lung cancer therapy.Cell death & disease · 2014Review
- Discovery of new membrane-associated proteins overexpressed in small-cell lung cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2014Article
- Proteomic approaches in biomarker discovery: new perspectives in cancer diagnostics.TheScientificWorldJournal · 2014Review
- Review
- Review
- Differential diagnostic CYFRA 21-1 level for benign and malignant pleural effusions: a meta-analysis in the Chinese population.Archives of medical science : AMS · 2012Article
- Epigenetic mechanisms in commonly occurring cancers.DNA and cell biology · 2012Review
- Evolving concepts in lung carcinogenesis.Seminars in respiratory and critical care medicine · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
During the last decade, high-throughput technologies including genomic, epigenomic, transcriptomic and proteomic have been applied to further our understanding of the molecular pathogenesis of this heterogeneous disease, and to develop strategies that aim to improve the management of patients with lung cancer. Ultimately, these approaches should lead to sensitive, specific and noninvasive methods for early diagnosis, and facilitate the prediction of response to therapy and outcome, as well as the identification of potential novel therapeutic targets. Genomic studies were the first to move this field forward by providing novel insights into the molecular biology of lung cancer and by generating candidate biomarkers of disease progression. Lung carcinogenesis is driven by genetic and epigenetic alterations that cause aberrant gene function; however, the challenge remains to pinpoint the key regulatory control mechanisms and to distinguish driver from passenger alterations that may have a small but additive effect on cancer development. Epigenetic regulation by DNA methylation and histone modifications modulate chromatin structure and, in turn, either activate or silence gene expression. Proteomic approaches critically complement these molecular studies, as the phenotype of a cancer cell is determined by proteins and cannot be predicted by genomics or transcriptomics alone. The present article focuses on the technological platforms available and some proposed clinical applications. We illustrate herein how the "-omics" have revolutionised our approach to lung cancer biology and hold promise for personalised management of lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.